These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 23658373

  • 41. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
    Pal SK, Figlin RA.
    Target Oncol; 2011 Mar; 6(1):5-16. PubMed ID: 21484496
    [Abstract] [Full Text] [Related]

  • 42. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L, Kim DNW, Hannan R, Watumull LM, Brugarolas J.
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract] [Full Text] [Related]

  • 43. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 44. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
    Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD.
    Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
    [Abstract] [Full Text] [Related]

  • 45. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
    Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ.
    BMC Cancer; 2011 Nov 30; 11():505. PubMed ID: 22129044
    [Abstract] [Full Text] [Related]

  • 46. Everolimus.
    Hasskarl J.
    Recent Results Cancer Res; 2014 Nov 30; 201():373-92. PubMed ID: 24756805
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
    Peuvrel L, Quéreux G, Brocard A, Saint-Jean M, Dréno B.
    Dermatology; 2012 Nov 30; 224(3):204-8. PubMed ID: 22614575
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
    Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A.
    J Clin Oncol; 2011 May 01; 29(13):1750-6. PubMed ID: 21444868
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
    Albiges L, Molinie V, Escudier B.
    Oncologist; 2012 May 01; 17(8):1051-62. PubMed ID: 22807514
    [Abstract] [Full Text] [Related]

  • 54. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
    Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E.
    Acta Oncol; 2012 Sep 01; 51(7):873-9. PubMed ID: 22909392
    [Abstract] [Full Text] [Related]

  • 55. Nontuberculous mycobacterial infection after therapy with temsirolimus for metastatic renal cell carcinoma.
    Buchler T, Homolka J, Fencl P, Rosova B, Hytych V, Abrahamova J.
    Tumori; 2013 Sep 01; 99(4):e159-63. PubMed ID: 24326853
    [Abstract] [Full Text] [Related]

  • 56. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B.
    J Natl Cancer Inst; 2012 Jan 18; 104(2):93-113. PubMed ID: 22235142
    [Abstract] [Full Text] [Related]

  • 57. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, Infanger M, Krüger M.
    Int J Mol Sci; 2017 Aug 10; 18(8):. PubMed ID: 28796163
    [Abstract] [Full Text] [Related]

  • 58. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
    Reddy GK, Mughal TI, Rini BI.
    Clin Genitourin Cancer; 2006 Sep 10; 5(2):110-3. PubMed ID: 17026798
    [Abstract] [Full Text] [Related]

  • 59. [Use of mTOR-inhibitors in solid tumors].
    Seidel C, Grünwald V.
    Med Monatsschr Pharm; 2011 Apr 10; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
    [Abstract] [Full Text] [Related]

  • 60. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B, Coskun U, Yildiz R, Buyukberber S, Baykara M, Benekli M.
    J Oncol Pharm Pract; 2011 Sep 10; 17(3):274-8. PubMed ID: 20215482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.